Affymetrix's Q1 Revenues Drop 8 Percent

The company continued on its strategy to diversify its products with a focus on cytogenetics and cancer in order to compensate for a "very soft" GWAS market.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories